Close
RNS Number : 9762E
ValiRx PLC
10 July 2019
 

 

 

 

VALIRX PLC

("ValiRx" or the "Company")

 

MARKETING AND COMMUNICATIONS UPDATE 

London, UK., 10 July 2019: ValiRx Plc (AIM: VAL), the AIM-quoted clinical stage biotechnology company is pleased to announce a marketing and communications update for shareholders. 

Dr Satu Vainikka, Chief Executive, will be delivering a presentation to investors at the SVS Securities and UK Investor Magazine investor evening on Thursday 18 July 2019 at the Skinners Hall, 8½ Dowgate Hill, London EC4R 2SP, which commences at 6:00pm (for registration) until 11:00pm. 

Those wishing to register for this complimentary event may do so through the following link: 

https://www.eventbrite.co.uk/e/uk-investor-magazine-svs-securities-summer-investor-evening-tickets-62427386995 

A copy of the presentation will be available to investors on the evening and will be available to view on the Company's website shortly after the event.

 

*** ENDS ***  

 

For more information, please contact:

 

ValiRx plc

Tel: +44 (0) 20 3008 4416

www.valirx.com

Dr Satu Vainikka, Chief Executive

Tel: +44 (0) 20 3008 4416

Tarquin Edwards, Head of Communications.

Tel: +44 (0) 7879 458 364

tarquin.edwards@valirx.com

 

 

Novum Securities Limited

Colin Rowbury

Tel: +44 (0) 20 7399 9400

 

Notes for Editors

About ValiRx

ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.

 

The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.

 

ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights.   They originate or derive from World class institutions, such as Cancer Research UK and Imperial College. 

 

Until recently, cancer treatments relied on non-specific agents, such as chemotherapy.  With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.

 

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRABXGDRLBGBGCC